Ariad halts Iclusig trial enrollment on blood-clot worries

Lingering safety concerns about Ariad Pharmaceuticals' ($ARIA) blockbuster leukemia drug Iclusig (ponatinib) boiled up into a crisis today. After investigators tracked a rising rate of blood clots among leukemia patients in ongoing clinical studies, the biotech slammed the brakes on new trial enrollment and rolled out a lower dosing schedule for current participants. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.